Akebia

AKBA NASDAQ
4.470
+0.210
+4.93%
Opening 14:14 06/25 EDT
Open
4.280
Prev Close
4.260
High
4.520
Low
4.200
Volume
456.44K
Avg Vol (3M)
1.15M
52 Week High
11.32
52 Week Low
4.090
% Turnover
0.39%
Market Cap
526.85M
1D
5D
1M
3M
1Y
5Y

Related

Webull offers Akebia AKBA stock price, real time market quotes, professional analyst ratings, and in-depth charts, You can share investing ideas in community to communicate with others and learn trading skills.

Company Profile

Akebia Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on the development and commercialization of therapeutics based on hypoxia-inducible factor (HIF) biology. The Company's lead product candidate, vadadustat, is indicated for the treatment of anemia in chronic kidney disease (CKD). It is involved in developing vadadustat as an oral therapy. The Company's vadadustat is a HIF-prolyl-hydroxylase (HIF-PH) inhibitor in Phase III development for the treatment of anemia of CKD. In addition to vadadustat, the Company is engaged in developing a HIF-based portfolio of product candidates that target serious diseases of unmet need. Its portfolio includes product candidates developed internally, such as AKB-6899, as well as in-licensed product candidates, including AKB-5169. AKB-5169 is a preclinical compound in development as an oral treatment for inflammatory bowel disease (IBD).
MORE >

Recently

Name
Price
%Change